Last reviewed · How we verify
LX211
LX211 is an investigational therapeutic in phase 3 development by Lux Biosciences with an undisclosed mechanism of action.
At a glance
| Generic name | LX211 |
|---|---|
| Sponsor | Lux Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding LX211's specific molecular mechanism. As a phase 3 candidate, it has progressed through early-stage development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis (PHASE3)
- A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis (PHASE3)
- A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis (PHASE3)
- A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LX211 CI brief — competitive landscape report
- LX211 updates RSS · CI watch RSS
- Lux Biosciences, Inc. portfolio CI